CTLA4 and neoplasm: In addition, tumor cDCs from patients with HCC were found to express inhibitory ligands such as PD-L1, Gal9 (ligand for TIM3), MHC-II (LAG3), CD86 and CD80 (CTLA-4) (Sun et al., 2021).